Bank of New York Mellon
OMGA

Bank of New York Mellon’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Bank of New York Mellon’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-125,546
Closed -$458K – 4292
2024
Q1 		$458K Sell
125,546
-4,899
-4% -$18.8K ﹤0.01% 3577
2023
Q4 		$393K Buy
130,445
+57,832
+80% +$117K ﹤0.01% 3686
2023
Q3 		$156K Sell
72,613
-21
-0% -$84 ﹤0.01% 4020
2023
Q2 		$407K Buy
72,634
+62,282
+602% +$487K ﹤0.01% 3703
2023
Q1 		$62.4K Sell
10,352
-7,170
-41% -$49.9K ﹤0.01% 4155
2022
Q4 		$100K Buy
+17,522
New +$98.3K ﹤0.01% 4118
2022
Q2 		– Sell
-55,277
Closed -$344K – 4720
2022
Q1 		$344K Buy
55,277
+39,934
+260% +$408K ﹤0.01% 3934
2021
Q4 		$174K Buy
15,343
+2,405
+19% +$45.7K ﹤0.01% 4319
2021
Q3 		$244K Buy
+12,938
New +$248K ﹤0.01% 4119

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of New York Mellon's OMGA Position: Q2 2024 in Review

Bank of New York Mellon sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q2 2024, closing a stake of 125,546 shares — an estimated $458K sold.

Bank of New York Mellon first reported a position in OMGA in Q3 2021 and held it in 9 quarters. The position peaked at $458K in Q1 2024. 68 funds tracked by Wall St. Rank hold OMGA as of Q2 2024.

  • Bank of New York Mellon reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 125,546 Omega Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $458K.
  • Bank of New York Mellon first reported a position in Omega Therapeutics, Inc. Common Stock in Q3 2021 and held it in 9 quarters.
  • Bank of New York Mellon's Omega Therapeutics, Inc. Common Stock position peaked at $458K in Q1 2024.
  • 68 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.